Study Evaluating of Calcineurin Inhibitors Versus Sirolimus in Renal Allograft Recipient
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00452361 |
Recruitment Status
:
Terminated
First Posted
: March 27, 2007
Results First Posted
: September 3, 2012
Last Update Posted
: September 3, 2012
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Kidney Transplantation | Drug: Sirolimus+MMF or MPS or AZA+Steroid Drug: Calcineurin Inhibitors (either cyclosporine or tacrolimus)+MMF or MPS or AZA+Steroid | Phase 4 |
This open-label, randomized, parallel-group, comparative, outpatient study will be conducted in multiple centers in Taiwan.
The study will randomize approximately 120 patients. 80 patients will be randomized to the SRL therapy group (conversion from CI- to SRL-based immunosuppression: group A) and 40 patients to the CI therapy group (continued CI therapy: group B).
Dosage and Administration
SRL Therapy: At the time of randomization on day 1, each patient will have been receiving:
- triple therapy with a CI (tacrolimus or CsA) that began at the time of transplantation or within 2 weeks thereafter AND
- corticosteroids corresponding to a dosage range of 2.5 to 15 mg/day for prednisone or prednisolone (2 to 12 mg/day for methylprednisolone) or the alternate day equivalent for at least 12 weeks before randomization, PLUS
- either MMF (minimum dose 500 mg/day)/MPS (minimum dose 360 mg/day) or AZA (minimum dose 50 mg/day) for at least 12 weeks before randomization.
SRL will be added to the immunosuppressive regimen for Group A. Group B will continue on this CI immunosuppressive regimen.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 31 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Randomized, Open-label, Comparative Evaluation of Conversion From Calcineurin Inhibitors to Sirolimus Versus Continued Use of Calcineurin Inhibitors in Renal Allograft Recipient |
Study Start Date : | April 2007 |
Actual Primary Completion Date : | August 2008 |
Actual Study Completion Date : | August 2008 |
Arm | Intervention/treatment |
---|---|
Experimental: 1
Sirolimus therapy
|
Drug: Sirolimus+MMF or MPS or AZA+Steroid
Corticosteroids will be administered according to local practice, within a daily maintenance dosage range of 2.5 to15 mg for prednisone or prednisolone (2 to 12 mg/day for methylprednisolone) or the alternate day equivalent.
|
Active Comparator: 2
Calcineurin Inhibitor therapy (either cyclosporine or tacrolimus)
|
Drug: Calcineurin Inhibitors (either cyclosporine or tacrolimus)+MMF or MPS or AZA+Steroid
The maintenance dose of:
Thereafter, at the discretion of the investigator, MMF/MPS or AZA may be:
|
- Change in Glomerular Filtration Rate (GFR) Change From Baseline [ Time Frame: 104 weeks ]GFR is an index of kidney function. GFR describes the flow rate of filtered fluid through the kidney. GFR can be measured directly or estimated using established formulas. GFR was calculated using Nankivell formula. A normal GFR is > 90 mL/min, although children and older people usually have a lower GFR. Lower values indicate poor kidney function. A GFR <15 is consistent with kidney failure.
- Change in Glomerular Filtration Rate (GFR) [ Time Frame: Baseline and Week 24 ]GFR is an index of kidney function. GFR describes the flow rate of filtered fluid through the kidney. GFR can be measured directly or estimated using established formulas. GFR was calculated using Nankivell formula. A normal GFR is > 90 mL/min, although children and older people usually have a lower GFR. Lower values indicate poor kidney function. A GFR <15 is consistent with kidney failure.
- Change in Glomerular Filtration Rate (GFR) [ Time Frame: Baseline and Week 52 ]GFR is an index of kidney function. GFR describes the flow rate of filtered fluid through the kidney. GFR can be measured directly or estimated using established formulas. GFR was calculated using Nankivell formula. A normal GFR is > 90 mL/min, although children and older people usually have a lower GFR. Lower values indicate poor kidney function. A GFR <15 is consistent with kidney failure.
- Change in Glomerular Filtration Rate (GFR) [ Time Frame: Baseline and Week 104 ]GFR is an index of kidney function. GFR describes the flow rate of filtered fluid through the kidney. GFR can be measured directly or estimated using established formulas. GFR was calculated using Nankivell formula. A normal GFR is > 90 mL/min, although children and older people usually have a lower GFR. Lower values indicate poor kidney function. A GFR <15 is consistent with kidney failure.
- Patient and Graft Survival [ Time Frame: Week 24 ]Patient survival defined as participants living with or without a functioning graft. Graft survival defined as those participants who did not experience graft loss. Graft loss defined as physical loss (nephrectomy), functional loss (necessitating maintenance dialysis for >8 weeks), retransplant or death during the first 12 months after randomization.
- Patient and Graft Survival [ Time Frame: Week 52 ]Patient survival defined as participants living with or without a functioning graft. Graft survival defined as those participants who did not experience graft loss. Graft loss defined as physical loss (nephrectomy), functional loss (necessitating maintenance dialysis for >8 weeks), retransplant or death during the first 12 months after randomization.
- Patient and Graft Survival [ Time Frame: Week 104 ]Patient survival defined as participants living with or without a functioning graft. Graft survival defined as those participants who did not experience graft loss. Graft loss defined as physical loss (nephrectomy), functional loss (necessitating maintenance dialysis for >8 weeks), retransplant or death during the first 12 months after randomization.
- Change From Baseline in Diastolic Blood Pressure at Week 24 [ Time Frame: Baseline and Week 24 ]Value at Week 24 minus value at baseline.
- Change From Baseline in Diastolic Blood Pressure at Week 52 [ Time Frame: Baseline and Week 52 ]Value at Week 52 minus value at baseline.
- Change From Baseline in Diastolic Blood Pressure at Week 104 [ Time Frame: Baseline and Week 104 ]Value at Week 104 minus value at baseline.
- Change From Baseline in Systolic Blood Pressure at Week 24 [ Time Frame: Baseline and Week 24 ]Value at Week 24 minus value at baseline.
- Change From Baseline in Systolic Blood Pressure at Week 52 [ Time Frame: Baseline and Week 52 ]Value at Week 52 minus value at baseline.
- Change From Baseline in Systolic Blood Pressure at Week 104 [ Time Frame: Baseline and Week 104 ]Value at Week 104 minus value at baseline.
- Change From Baseline in the Severity and Progression of Biopsy-Confirmed Chronic Allograft Nephropathy (CAN) at Week 104 [ Time Frame: Baseline and Week 104 ]
- Occurence of Acute Rejection or Premature Withdrawal From Study Medication for Any Reason by Week 52 [ Time Frame: Weeks 52 ]
- Occurence of Acute Rejection or Premature Withdrawal From Study Medication for Any Reason by Week 104 [ Time Frame: Week 104 ]
- Incidence and Severity of Biopsy-Confirmed Acute Rejection at Week 24 [ Time Frame: Week 24 ]
- Incidence and Severity of Biopsy-Confirmed Acute Rejection at Week 52 [ Time Frame: Week 52 ]
- Incidence and Severity of Biopsy-Confirmed Acute Rejection at Week 104 [ Time Frame: Week 104 ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Subjects must be at least 18 years of age.
- Subjects who are 6 to 60 months after renal transplantation.
- Subjects who have a stable graft function.
Exclusion Criteria:
- Subjects with active major infection, including HIV, decreased platelets, elevated lipids, or multiple organ transplants.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00452361
Taiwan | |
Select Cities, Taiwan |
Study Director: | Medical Monitor | Wyeth is now a wholly owned subsidiary of Pfizer |
Responsible Party: | Wyeth is now a wholly owned subsidiary of Pfizer |
ClinicalTrials.gov Identifier: | NCT00452361 History of Changes |
Other Study ID Numbers: |
0468H-101864 |
First Posted: | March 27, 2007 Key Record Dates |
Results First Posted: | September 3, 2012 |
Last Update Posted: | September 3, 2012 |
Last Verified: | July 2012 |
Additional relevant MeSH terms:
Tacrolimus Cyclosporins Cyclosporine Sirolimus Everolimus Calcineurin Inhibitors Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs |
Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Antifungal Agents Anti-Infective Agents Dermatologic Agents Antirheumatic Agents Anti-Bacterial Agents Antibiotics, Antineoplastic Antineoplastic Agents |